1
Okada Hiroaki, Kamei Shigeru, Yoshioka Toshio: Intravascular embolizing agent containing angiogenesis inhibiting substance.. Takeda Chemical Industries, February 12, 1992: EP0470569-A1 (109 worldwide citation)

The present invention relates to an intravascular embolizing agent containing an angiogenesis-inhibiting substance and an intravascular embolizing substance. The agent strengthens the antitumor effect of an angiogenesis-inhibiting substance and serves to reduce the dose and undesirable side effects. ...


2
Cherukuri Subraman Rao, Chau Tommy Linkwong, Raman Krishna P, Orama Angel Manuel: Multiple encapsulated flavor delivery system and method of preparation.. Warner Lambert Co, October 23, 1991: EP0453397-A1 (40 worldwide citation)

A free-flowing particulate delivery system for providing enhanced flavor and sweetness to comestible compositions comprising a powdered flavor composition encapsulated in a matrix comprising an outer hydrophilic coating containing up to the solubility limit of the coating of an intense sweetener. Th ...


3
Belloni Paula Nanette, Hirschfeld Donald Roy, Nestor Jr John Joseph, Peltz Gary Allen: Cationic lipids for gene therapy. Hoffmann La Roche, June 10, 1998: EP0846680-A1 (28 worldwide citation)

This invention provides novel cationic lipids, particularly guanidino lipids, and methods for their preparation. Also provided are polyanionic-lipid complexes comprising the lipids of the invention, their preparation and use to deliver biologically active substances, particularly nucleic acids to ce ...


4
BARTHOLOMAEUS JOHANNES, KUGELMANN HEINRICH, LANGNER KLAUS DIETER: FORME GALENIQUE PROTEGEE CONTRE UN USAGE DETOURNE, DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE. GRUENENTHAL, GRUENENTHAL, FETHERSTONHAUGH & CO, April 12, 2016: CA2502965 (27 worldwide citation)

The invention relates to a dosage form that is safeguarded from abuse. In addition to one or more active substances that could be subject to abuse, said form comprises two or more of the following constituents (a)-(d): (a) at least one substance that irritates the nasal and/or pharyngeal region; (b) ...


5
Oshlack Benjamin, Chasin Mark, Huang Hua Pin, Sackler David: Melt-extruded orally administrable opioid formulations. Euro Celtique, October 1, 2003: EP1348429-A2 (25 worldwide citation)

Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques are disclosed. Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrus ...


6
Minamitake Yoshiharu, Tsukada Yoshio, Kanai Yasushi, Yanagawa Akira: Medicinal compositions for nasal absorption. Daiichi Suntory Pharma, Dott Res Lab, October 13, 2004: EP1466610-A1 (24 worldwide citation)

A pharmaceutical composition for nasal administration exhibits an improved bioavailability of a biologically active polypeptide, the active ingredient of the pharmaceutical composition. Specifically, the composition is prepared by uniformly dispersing and embedding a biologically active acidic polyp ...


7
Mccrea Andrew D, Diulus Michael P: Stable anhydrous compositions for topical delivery of active materials.. Curtis Helene, December 5, 1990: EP0400546-A1 (23 worldwide citation)

An anhydrous, topically-effective composition that resists phase separation and exhibits improved sensory properties comprising a topically-active compound, such as an astringent salt; a finely-divided silica; a suspending wax composition; and a suitable volatile liquid carrier vehicle, such as a vo ...


8
Hauer Birgit, Posanski Ulrich: Cyclosporin compositions. Sandoz, October 24, 1990: GB2230440-A (23 worldwide citation)

La présente invention a pour objet de nouvelles compositions pharmaceutiques comprenant : a. une cyclosporine comme substance active, b. un monoester d'un acide gras avec un saccharide et c. un diluant ou véhicule.


9
Kasraian Kasra, Thombre Avinash G: Palatable pharmaceutical compositions for companion animals. Pfizer Prod, October 9, 2002: EP1247456-A2 (22 worldwide citation)

The present invention is directed to pharmaceutical compositions, which are palatable to companion animals wherein the pharmaceutical composition comprises pharmaceutically effective amounts of pharmaceutically active agents and palatability improving agents.


10
Yumoto Takashi, Miyake Toshio: Oral material with improved taste, method for improving taste of the same, and method for using enzyme-treated ginkgo leaves extract. Toyo Seito, Hayashibara Biochem Lab, July 2, 2003: JP2003-180288 (21 worldwide citation)

PROBLEM TO BE SOLVED: To provide an oral material containing a high-sweetness sweetener, such as a food/drink, crude drug-containing food/drink or dentifrice, ameliorated in bitterness and aftersweetness, and increased in sweetness body in the case of containing a sugar alcohol.SOLUTION: This oral m ...